CliffBio
biologic

Panzyga

Immune Globulin Intravenous (Human)-ifas

Loss of exclusivityAugust 2030projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand namePanzyga
Active ingredientImmune Globulin Intravenous (Human)-ifas
Strength1G ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2018
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Panzyga patent cliff — loss of exclusivity August 2030 | CliffBio